var data={"title":"Ketamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ketamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6420?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">see &quot;Ketamine: Drug information&quot;</a> and <a href=\"topic.htm?path=ketamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ketamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45497290\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ketalar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185726\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ketalar;</li>\n      <li>Ketamine Hydrochloride Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053466\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">General Anesthetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675070\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Individualize dose and titrate to effect. Some neonatal experts do not recommend the use of ketamine in neonates; an increase in neuronal apoptosis has been observed in neonatal animal studies (Patel 2009). The American College of Emergency Physicians considers the use of ketamine in infants &lt;3 months of age to be an absolute contraindication, due to the higher risk of airway complications (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia, adjunct:</b> Limited data available: IV: 0.5 to 2 mg/kg/dose has been reported. A study of 23 patients [mean age: 3.2 years (9 days to 7 years)] undergoing MRI received a fixed dose of 0.5 mg/kg of ketamine prior to propofol bolus and infusion. A single case report describes ketamine (1 to 2 mg/kg) adjunct use with sevoflurane in a 1-day old neonate (GA: 33 weeks) undergoing pacemaker placement (Castilla 2004; Tomatir 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Procedural sedation/analgesia:</b> Limited data available: IV: 0.5  to 2 mg/kg/dose (Anand 2001; Hall 2012; Lago 2009); reported use includes intubation, during cardiac catheterization, and ROP corrective procedures (Barois 2013; Jobeir 2003; Lyon 2008; Pees 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053458\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">see &quot;Ketamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Titrate dose to effect. May be used in combination with anticholinergic agents to decrease hypersalivation. <b>Note:</b> The American College of Emergency Physicians considers the use of ketamine in infants &lt;3 months of age to be an absolute contraindication, due to the higher risk of airway complications (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pre-anesthetic sedation:</i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;6 months: 3 mg/kg/dose (half dose per nostril) administered at least 15 minutes prior to mask induction (Diaz 1997; Lin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;2 years: 3 to 5 mg/kg/dose (half dose per nostril) administered at least 15 minutes prior to mask induction (Diaz 1997; Gautam 2007; Lin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 7 years: 3 to 6 mg/kg/dose (half dose per nostril) administered 15 to 40 minutes prior to induction (Diaz 1997; Gautam 2007; Lin 1990; Roelofse 2004; Weksler 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children &le;8 years: 6 to 8 mg/kg/dose 20 to 30 minutes prior to surgery. Dosing based on two prospective, randomized, double-blind, placebo-controlled, dose finding trials. The larger trial compared 4 mg/kg, 6 mg/kg, and 8 mg/kg (n=20 in each group; age range: 2 to 8 years) and found that patients who received 8 mg/kg were significantly more calm, but also had slightly longer recovery times. Sedation was effective within 10 minutes of administration in 80% and 45% of the patients in the 8 mg/kg and 6 mg/kg, groups respectively, but was not effective in the 4 mg/kg group (Turhano&#287;lu 2003). The other study compared 3 mg/kg and 6 mg/kg (n=15 in each group, age range: 1 to 7 years) and found that patients who received 6 mg/kg had satisfactory sedation without prolonged recovery times, but the 3 mg/kg dose did not provide uniform sedation nor offer a significant improvement in premedicated emotional state compared to placebo (Gutstein 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Administer 15 to 45 minutes prior to surgery as a single agent; when used in combination with other sedatives, lower doses should be considered. Efficacy was reported in trials comparing rectal ketamine to rectal doses of other agents (fentanyl/droperidol, midazolam) (Lin 1990; Tanaka 2000; Van der Bijl 1991; Wang 2010; Zanette 2010). Reported effective range:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 2 to 6 months: 8 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;7 months and Children &le;9 years: 8 to 10 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Although lower doses of 4 to 7 mg/kg/dose have been reported, they were less effective. In some patients, the 10 mg/kg/dose was associated with prolonged postoperative sedation. When used in combination with midazolam, a lower rectal dose of 3 mg/kg/dose has been effective (Beebe 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction of anesthesia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents &lt;16 years: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 5 to 10 mg/kg has been reported and suggested by experts (Cot&eacute; 2013; Lin 2005; Sungur Ulke 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 to 3 mg/kg has been reported and suggested by experts (Cot&eacute; 2013; Lin 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 6.5 to 13 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 to 4.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance of anesthesia:</i> Adolescents &ge;16 years: May administer supplemental doses of one-half to the full induction dose as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endotracheal intubation:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 to 2 mg/kg as part of rapid sequence sedation (AAP [Hegenbarth 2008]; Ballow 2012; Fuhrman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation/analgesia, procedural:</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Due to risk of airway obstruction, laryngospasm, and apnea, ACEP only recommends use in patients &ge;3 months of age (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ketamine without propofol: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 4 to 5 mg/kg as a single dose; may give a repeat dose (range: 2 to 5 mg/kg) if sedation inadequate after 5 to 10 minutes or if additional doses are required (ACEP [Green 2011]). Some have recommended smaller doses (2 to 2.5 mg/kg) for minor procedures (eg, wound suture with local anesthetic) (McGlone 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 to 2 mg/kg over 30 to 60 seconds. If initial sedation inadequate or repeated doses are necessary to accomplish a longer procedure, may administer additional doses of 0.5 to 1 mg/kg every 5 to 15 minutes as needed (ACEP [Green 2011]; Asadi 2013; Berkenbosch 2004, Koruk 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: Infants &ge;3 months and Children: 3 to 6 mg/kg (half dose per nostril). Studies have primarily used this route in the dental or radiology setting. In the largest, randomized, placebo-controlled, double-blind trial, intranasal ketamine was compared to intranasal dexmedetomidine for use prior to propofol for MRI sedation. The ketamine group (n=52, mean age: 4.9 &plusmn; 2.4 years) received 5 mg/kg intranasally 30 minutes prior to IV cannulation. Both treatment groups required significantly less propofol during the MRI than the placebo group and had high rates of satisfaction from anesthesiologists and parents (Gyanesh 2014). Another study in the radiology setting was a prospective, observational trial of sedation prior to CT scan. Patients (n=30, mean age: 2.15 years; range: 3 months to 12 years) received intranasal ketamine 5 mg/kg in combination with midazolam. For patients who remained uncooperative after 20 minutes, an IV dose of ketamine was administered. Intranasal therapy alone was effective for 83% of patients (Louon 1994). In the dental setting, three randomized, blinded, comparative studies have found intranasal ketamine (3 to 6 mg/kg) as monotherapy in children (ages 17 months to 11 years) to be either as effective or more effective than intranasal midazolam (Abrams 1993, Bahetwar 2011, Surendar 2014). In all of these studies, intranasal ketamine was well tolerated with no significant adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children and Adolescents: 5 mg/kg with oral midazolam given 30 to 45 minutes before the procedure. Dosing based on two prospective, randomized, blinded studies involving patients aged 1 to 10 years with either laceration repair or burn wound care (Barkan 2014; Norambuena 2013). A lower dose (3 mg/kg) in addition to midazolam was effective in a study comparing different routes (IV, oral, rectal) of ketamine plus midazolam for invasive procedures in oncology patients. The oral group included 24 patients (mean age: 3.9 &plusmn; 1.3 years); incidence of optimal sedation was similar between groups (75% for the oral group) (Ozdemir 2004). <b>Note:</b> A higher dose (10 mg/kg) has been used successfully as monotherapy prior to procedures in pediatric oncology patients (n=35, age: 14 months to 17 years; mean age: 6.5 years) (Tobias 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Children 1 to 8 years: 1.5 to 3 mg/kg with midazolam as a single dose 20 minutes prior to painful procedure. Dosing based on two studies. The first was completed in children with burns requiring dressing changes (n=47 procedures in 30 patients, mean age: 1.9 years, range: 10 months to 7.3 years). Patients received 0.75 mg/kg of the S(+) isomer (equivalent to 1.5 mg/kg of racemic ketamine) along with rectal midazolam 20 minutes prior to dressing changes; 94% of the procedures were reported to have good or excellent analgesia (Heinrich 2004). The second study compared different routes (IV, oral, rectal) of ketamine plus midazolam for invasive procedures in oncology patients. The rectal group included 24 patients (mean age: 3.7 &plusmn; 1.1 years) who received 3 mg/kg of ketamine in addition to midazolam. Incidence of optimal sedation was similar between groups (79% for the rectal group) (Ozdemir 2004). In both of these studies, rectal ketamine was well tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ketamine with propofol (&quot;ketofol&quot;):</i> Infants &ge;3 months, Children, and Adolescents: IV: 0.5 to 0.75 mg/kg of each agent. This combination has been used to decrease the dose of each agent required. It has been proposed that these lower doses help decrease adverse effects, ketamine may decrease the propofol-related hypotension and respiratory depression, and propofol may decrease the ketamine associated nausea and emergence reactions (ACEP [Godwin 2014]; Alletag 2012; Shah 2011; Willman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation/analgesia, critically ill patients:</b> Very limited data available: Infants &ge;5 months, Children, and Adolescents: Initial dose: IV: 0.5 to 2 mg/kg, then continuous IV infusion: 5 to 20 mcg/kg/minute; start at lower dosage listed and titrate to effect (Denmark 2006; Rock 1986; Tobias 1990; White 1982); doses as high as 60 mcg/kg/minute have been reported in patients with refractory bronchospasm (Youssef-Ahmed 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Anesthesia:</b> May be used in combination with anticholinergic agents to decrease hypersalivation. <b>Note:</b> Titrate dose for desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction of anesthesia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 6.5 to 13 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 to 4.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance of anesthesia:</i> May administer supplemental doses of one-half to the full induction dose or a continuous infusion of 0.1 to 0.5 mg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185708\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ketalar: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (1 mL); 100 mg/2 mL (2 mL); 100 mg/10 mL (10 mL); 20 mg/2 mL (2 mL); 50 mg/5 mL in NaCl 0.9% (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185693\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185765\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053471\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal (using parenteral dosage form): Use the 50 or 100 mg/mL solution; may administer undiluted or further dilute in NS to a concentration of 20 mg/mL (Bahetwar 2011; Louon 1994; Surendar 2014). Administer half dose in each nostril using a needleless syringe.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (using parenteral dosage form): Use the 100 mg/mL IV solution and mix the appropriate dose in 0.2 to 0.4 mL/kg of cola, sour cherry juice, or other beverage (Gutstein 1992; Tobias 1992, Turhano&#287;lu 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: May administer the 10 mg/mL and 50 mg/mL undiluted. Administer slowly over 60 seconds, do not exceed 0.5 mg/kg/minute; more rapid administration may result in respiratory depression and enhanced pressor response. Some experts suggest administration over 2 to 3 minutes (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: May be administered as a continuous IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal (using parenteral dosage form): May use the 50 mg/mL solution undiluted or use the 100 mg/mL solution and further dilute prior to administration (Tanaka 2000; Van der Bijl 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185722\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053470\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Induction and maintenance of general anesthesia (FDA approved in ages &ge;16 years and adults); has also been used for procedural sedation/analgesia (including endotracheal intubation) and sedation of critically ill patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185772\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ketalar may be confused with Kenalog, ketorolac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV, intranasal/inhaled administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185769\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, hypotension, increased blood pressure, increased pulse</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drug dependence, hypertonia (tonic-clonic movements sometimes resembling seizures), increased cerebrospinal fluid pressure, prolonged emergence from anesthesia (includes confusion, delirium, dreamlike state, excitement, hallucinations, irrational behavior, vivid imagery)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema (transient), morbilliform rash (transient), rash at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Central diabetes insipidus (Hatab 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, nausea, sialorrhea (Hatab 2014), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary (reactions can be severe in patients with a history of chronic ketamine use/abuse): Bladder dysfunction (reduced capacity), cystitis (including cystitis noninfective, cystitis interstitial, cystitis ulcerative, cystitis erosive, cystitis hemorrhagic), dysuria, hematuria, urinary frequency, urinary incontinence, urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Laryngospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Diplopia, increased intraocular pressure, nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Hydronephrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Airway obstruction, apnea, respiratory depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185713\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ketamine or any component of the formulation; conditions in which an increase in blood pressure would be hazardous</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In the emergency department, the following additional absolute contraindications according to the American College of Emergency Physicians have been asserted (ACEP [Green 2011]): Infants &lt;3 months of age; known or suspected schizophrenia (even if currently stable or controlled with medications)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of cerebrovascular accident; severe cardiac decompensation; surgery of the pharynx, larynx, or bronchial tree unless adequate muscle relaxants are used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185697\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Airway complications: When used for procedural sedation for major procedures involving the posterior pharynx (eg, endoscopy) or when used for patients with an active pulmonary infection or disease (including upper respiratory disease or asthma), the use of ketamine increases the risk of laryngospasm. Patients with a history of airway instability, tracheal surgery, or tracheal stenosis may be at a higher risk of airway complications. The American College of Emergency Physicians considers these situations relative contraindications for the use of ketamine (ACEP [Green 2011]). The manufacturer recommends against the use of ketamine alone in surgery or diagnostic procedures of the pharynx, larynx, or bronchial tree; mechanical stimulation of the pharynx should be avoided, whenever possible, if ketamine is used alone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). When used for outpatient surgery, the patient should be accompanied by a responsible adult. Driving, operating hazardous machinery, or engaging in hazardous activities should not be undertaken for &ge;24 hours after anesthesia, according to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dependence: May cause dependence (withdrawal symptoms on discontinuation) and tolerance with prolonged use. A withdrawal syndrome with psychotic features has been described following discontinuation of long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Emergence reactions: Postanesthetic emergence reactions, which can manifest as vivid dreams, hallucinations, and/or frank delirium, occur; these reactions are less common in patients &lt;16 years of age and &gt;65 years and when given IM (White 1982). Emergence reactions, confusion, or irrational behavior may occur up to 24 hours postoperatively and may be reduced by pretreatment with a benzodiazepine, use of ketamine at the lower end of the dosing range, and minimizing verbal and tactile stimulation of the patient during the recovery period. Avoid use in patients with schizophrenia; may exacerbate psychotic symptoms (Lahti 1995; Malhotra 1997). The American College of Emergency Physicians considers the use of ketamine in patients with known or suspected schizophrenia (even if currently stable or controlled with medications) an absolute contraindication (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Some consider the use of ketamine in patients with CNS masses, CNS abnormalities, or hydrocephalus a relative contraindication due to multiple reports that ketamine may increase intracranial pressure in these patients (ACEP [Green 2011]). However, assuming adequate ventilation, some evidence suggests that ketamine has minimal effects on intracranial pressure and may even improve cerebral perfusion and reduce intracranial pressure (Albanese 1997; Bowles 2012; Zeiler 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased ocular pressure: Use with caution in patients with increased intraocular pressure (IOP). Some recommend avoiding use in patients with an open eye injury or other ophthalmologic disorder where an increase in IOP would prove to be detrimental; however, the effects of ketamine on IOP is mixed with some evidence demonstrating no clinically significant effect on IOP (ACEP [Green 2011]; Cunningham 1986; Drayna 2012; Miller 2010; Nagdeve 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: The American College of Emergency Physicians considers the use of ketamine in patients with porphyria a relative contraindication due to enhanced sympathomimetic effect produced by ketamine (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Rapid IV administration or overdose may cause respiratory depression or apnea. Resuscitative equipment should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: The American College of Emergency Physicians considers the use of ketamine in patients with a thyroid disorder or receiving a thyroid medication a relative contraindication due to enhanced sympathomimetic effect produced by ketamine (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, catecholamine depletion, hypertension, and tachycardia. Cardiac function should be continuously monitored in patients with increased blood pressure or cardiac decompensation. Ketamine increases blood pressure, heart rate, and cardiac output thereby increasing myocardial oxygen demand. The mechanism by which ketamine causes a sympathetic surge to stimulate the cardiovascular system has yet to be elucidated. The use of concurrent benzodiazepine, inhaled anesthetics, and propofol or administration of ketamine as a continuous infusion may reduce these cardiovascular effects (Miller 2010). The American College of Emergency Physicians recommends avoidance in patients who are already hypertensive and in older adults with risk factors for coronary artery disease (ACEP [Green 2011]). In a scientific statement from the American Heart Association, ketamine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrospinal fluid (CSF) pressure elevation: Use with caution in patients with CSF pressure elevation; an increase in CSF pressure may be associated with use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Use with caution in the chronic alcoholic or acutely alcohol-intoxicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Use requires careful patient monitoring, should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with deep anesthesia. Consult local regulations and individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26021157\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's or fetus&rsquo; brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer's labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">May produce postanesthetic emergence reactions; may be minimized by limiting verbal, tactile, and visual patient stimulation during recovery, or by pretreatment with a benzodiazepine (using lower recommended doses of ketamine). Severe emergent reactions may require treatment with a small hypnotic dose of a short or ultrashort acting barbiturate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data suggest that exposure to ketamine during critical neurodevelopment periods (eg, neonates, infants, and young children) may negatively affect neurodevelopment; mechanisms and risk factors have not been fully defined (eg, number of exposures to ketamine); clinical decisions regarding use should be judicious and patients monitored closely. A study followed infants and young children &lt;24 months of age who received ketamine anesthesia for outpatient laser surgery treatments for benign facial growth (n=49, including 13 subjects with three exposures to ketamine); results showed decreases in both the mental development and psychomotor development index scores (measured by Bayley Scales) after three exposures, but not after one or two exposures of ketamine when compared to preexposure scores (Yan 2014). Animal data suggests that exposure of the developing brain to anesthetics like ketamine (especially during the critical time of synaptogenesis) may result in long-term impairment of cognitive function (Patel 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185759\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (major), CYP2C9 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185702\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13398&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Ketamine may enhance the adverse/toxic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5994626\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Adverse events have been observed in animal reproduction studies. Ketamine crosses the placenta and can be detected in fetal tissue. Ketamine produces dose dependent increases in uterine contractions; effects may vary by trimester. The plasma clearance of ketamine is reduced during pregnancy. Dose related neonatal depression and decreased APGAR scores have been reported with large doses administered at delivery (Ghoneim 1977; Little 1972; White 1982). Although ketamine has been used during vaginal delivery and cesarean section, use in pregnancy, including obstetrics (either vaginal or abdominal delivery) is not recommended by the manufacturer (Akamatsu 1974; Little 1972; Mercier 1998).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity, may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with ketamine during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053465\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiovascular effects, heart rate, blood pressure, respiratory rate, transcutaneous O<sub>2</sub> saturation, emergence reactions </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185696\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces a cataleptic-like state in which the patient is dissociated from the surrounding environment by direct action on the cortex and limbic system. Ketamine is a noncompetitive NMDA receptor antagonist that blocks glutamate. Low (subanesthetic) doses produce analgesia, and modulate central sensitization, hyperalgesia and opioid tolerance. Reduces polysynaptic spinal reflexes. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185712\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Anesthetic effect: Within 30 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Anesthetic effect: 3 to 4 minutes; Analgesia: Within 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Analgesic effect: Within 10 minutes (Carr 2004); Sedation: Children 2 to 6 years: 5 to 8 minutes (Bahetwar 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Analgesia: Within 30 minutes; Sedation: Children 2 to 8 years (Turhanoglu 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">4 mg/kg/dose: 12.9 &plusmn; 1.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">6 mg/kg/dose: 10.4 &plusmn; 2.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">8 mg/kg/dose: 9.5 &plusmn; 1.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Anesthetic effect: 5 to 10 minutes; Recovery: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Anesthetic effect: 12 to 25 minutes; Analgesia: 15 to 30 minutes; Recovery: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Analgesic effect: Up to 60 minutes (Carr 2004); Recovery: Children 2 to 6 years: 34 to 46 minutes (Bahetwar 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 2.4 L/kg (Wagner 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 27% (Brunton 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via N-dealkylation (metabolite I [norketamine]), hydroxylation of the cyclohexone ring (metabolites III and IV), conjugation with glucuronic acid and dehydration of the hydroxylated metabolites to form the cyclohexene derivative (metabolite II); metabolite I (norketamine) is 33% as potent as parent compound. When administered orally, norketamine concentrations are higher compared to other routes of administration due to extensive first-pass metabolism in the liver (Blonk 2010; Soto 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 93%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 20% to 30% (Miller 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Children, Adolescents, and Adults: Mean range: 35% to 50% (Malinovsky 1996; Miller 2010; Nielsen 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Children 2 to 9 years: 25% (Malinovsky 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Alpha: 10 to 15 minutes; Beta: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 5 to 30 minutes (Clements 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: 10 to 14 minutes (Huge 2010); Children 2 to 9 years: ~20 minutes (Malinovsky 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: ~30 minutes (Soto 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Children 2 to 9 years: ~45 minutes (Malinovsky 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (91%); feces (3%) (Ghoneim 1977)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422244\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ketalar Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $21.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $6.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $11.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ketamine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $20.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $4.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $9.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Ketamine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/2 mL (2 mL): $6.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Ketamine HCl-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MG/2ML 0.9% (2 mL): $5.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/5ML 0.9% (5 mL): $5.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MG/10ML 0.9% (10 mL): $8.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185716\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aneket (ET, LK);</li>\n      <li>Anesject (ID);</li>\n      <li>Brevinaze (ZA);</li>\n      <li>Calypsol (AE, BB, BG, BH, BM, BS, BZ, CY, CZ, EG, GY, HN, HU, IQ, IR, JM, JO, KW, LB, LY, OM, PK, PL, PR, QA, RO, RU, SA, SR, SY, TT, VN, YE);</li>\n      <li>Cost (AR, BR);</li>\n      <li>Etamine (PH);</li>\n      <li>Ivanes (ID);</li>\n      <li>Kain (BD);</li>\n      <li>Kanox (MY);</li>\n      <li>Katalar (QA);</li>\n      <li>Keiran (VE);</li>\n      <li>Ketalar (AE, AU, BB, BD, BE, BH, BM, BS, BZ, CH, CY, DK, EE, EG, FI, FR, GB, GR, GY, HK, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KW, LB, LU, LY, MT, MY, NO, NZ, OM, PE, PT, QA, SA, SE, SK, SR, SY, TR, TT, TW, UY, YE);</li>\n      <li>Ketalin (MX);</li>\n      <li>Ketam (BD, ET);</li>\n      <li>Ketamax (PH);</li>\n      <li>Ketamin-S (+) (PY);</li>\n      <li>Ketamina (CU);</li>\n      <li>Ketanest (AT, HR, NL, PL);</li>\n      <li>Ketanir (LK);</li>\n      <li>Ketaride (BD);</li>\n      <li>Ketashort (CO);</li>\n      <li>Ketava (MY);</li>\n      <li>Ketavit (LK);</li>\n      <li>Ketmin (IN);</li>\n      <li>Ketolar (ES);</li>\n      <li>Ketomin (KR);</li>\n      <li>Narkamon (DE, PL);</li>\n      <li>Tekam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Velonarcon (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abrams R, Morrison JE, Villasenor A, Hencmann D, Da Fonseca M, Mueller W. Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. <i>Anesth Prog</i>. 1993;40(3):63-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/7645790 /pubmed\" target=\"_blank\" id=\"7645790 \">7645790 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akamatsu TJ, Bonica JJ, Rehmet R, Eng M, Ueland K. Experiences with the use of ketamine for parturition. I. Primary anesthetic for vaginal delivery. <i>Anesth Analg</i>. 1974;53(2):284-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/4856139/pubmed\" target=\"_blank\" id=\"4856139\">4856139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use for pediatric sedation. <i>Pediatr Emerg Care</i>. 2012;28(12):1391-1395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/23222112 /pubmed\" target=\"_blank\" id=\"23222112 \">23222112 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anand KJ, International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. <i>Arch Pediatr Adolesc Med</i>. 2001;155(2):173-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/11177093 /pubmed\" target=\"_blank\" id=\"11177093 \">11177093 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asadi P, Ghafouri HB, Yasinzadeh M, Kasnavieh SM, Modirian E. Ketamine and atropine for pediatric sedation: a prospective double-blind randomized controlled trial. <i>Pediatr Emerg Care</i>. 2013;29(2):136-139.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/23364373/pubmed\" target=\"_blank\" id=\"23364373\">23364373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahetwar SK, Pandey RK, Saksena AK, Chandra G. A comparative evaluation of intranasal midazolam, ketamine and their combination for sedation of young uncooperative pediatric dental patients: a triple blind randomized crossover trial. <i>J Clin Pediatr Dent</i>. 2011;35(4):415-420.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/22046702 /pubmed\" target=\"_blank\" id=\"22046702 \">22046702 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ballow SL, Kaups KL, Anderson S, Chang M. A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients.<i> J Trauma Acute Care Surg</i>. 2012;73(6):1401-1405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/23188232 /pubmed\" target=\"_blank\" id=\"23188232 \">23188232 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barkan S, Breitbart R, Brenner-Zada G, et al. A double-blind, randomised, placebo-controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair. <i>Emerg Med J</i>. 2014 Aug;31(8):649-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/23686730 /pubmed\" target=\"_blank\" id=\"23686730 \">23686730 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barois J, Tourneux P. Ketamine and atropine decrease pain for preterm newborn tracheal intubation in the delivery room: an observational pilot study. <i>Acta Paediatr</i>. 2013;102(12):e534-538.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/24015945/pubmed\" target=\"_blank\" id=\"24015945\">24015945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beebe DS, Belani KG, Chang PN, et al. Effectiveness of preoperative sedation with rectal midazolam, ketamine, or their combination in young children. <i>Anesth Analg</i>. 1992;75(6):880-884.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/1443705 /pubmed\" target=\"_blank\" id=\"1443705 \">1443705 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkenbosch JW, Graff GR, Stark JM. Safety and efficacy of ketamine sedation for infant flexible fiberoptic bronchoscopy. <i>Chest</i>. 2004;125(3):1132-1137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15006978 /pubmed\" target=\"_blank\" id=\"15006978 \">15006978 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19879174\"></a>Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: a review. <i>Eur J Pain</i>. 2010;14(5):466-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/19879174/pubmed\" target=\"_blank\" id=\"19879174\">19879174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunton LL, Lazo JS, Park KL, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 11th ed. New York, NY: McGraw-Hill Medical; 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15109503\"></a>Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. <i>Pain</i>. 2004;108(1-2):17-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15109503/pubmed\" target=\"_blank\" id=\"15109503\">15109503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castilla M, Jerez M, Ll&aacute;cer M, et al, &quot;Anaesthetic Management in a Neonate With Congenital Complete Heart Block,&quot; <i>Paediatr Anaesth</i>, 2004, 14(2):172-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/14962334/pubmed\" target=\"_blank\" id=\"14962334\">14962334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Elsevier; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham AJ, Barry P. Intraocular pressure--physiology and implications for anaesthetic management. <i>Can Anaesth Soc J</i>. 1986 Mar;33(2):195-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/3516335/pubmed\" target=\"_blank\" id=\"3516335\">3516335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. <i>J Emerg Med</i>. 2006;30(2):163-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/16567251 /pubmed\" target=\"_blank\" id=\"16567251 \">16567251 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diaz JH. Intranasal ketamine preinduction of paediatric outpatients. <i>Paediatr Anaesth</i>. 1997;7(4):273-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/9243683 /pubmed\" target=\"_blank\" id=\"9243683 \">9243683 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gautam SN, Bhatta S, Sangraula D, Shrestha BC, Rawal SB. Intranasal midazolam vs ketamine as premedication in paediatric surgical procedure for child separation and induction. <i>Nepal Med Coll J</i>. 2007;9(3):179-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/18092436 /pubmed\" target=\"_blank\" id=\"18092436 \">18092436 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghoneim MM and Korttila K, &quot;Pharmacokinetics of Intravenous Anaesthetics: Implications for Clinical Use,&quot; <i>Clin Pharmacokinet</i>, 1977, 2(5):344-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/21053/pubmed\" target=\"_blank\" id=\"21053\">21053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2014;63(2):247-258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/24438649 /pubmed\" target=\"_blank\" id=\"24438649 \">24438649 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. <i>Ann Emerg Med</i>. 2011;57(5):449-461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/21256625 /pubmed\" target=\"_blank\" id=\"21256625 \">21256625 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gutstein HB, Johnson KL, Heard MN, et al, &ldquo;Oral Ketamine Preanesthestic Medication in Children,&rdquo; <i>Anesthesiology</i>, 1992, 76(1):28-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/1729932/pubmed\" target=\"_blank\" id=\"1729932\">1729932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gyanesh P, Haldar R, Srivastava D, Agrawal PM, Tiwari AK, Singh PK. Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: a double-blind, randomized, placebo-controlled trial. <i>J Anesth</i>. 2014;28(1):12-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/23800984 /pubmed\" target=\"_blank\" id=\"23800984 \">23800984 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall RW. Anesthesia and analgesia in the NICU. <i>Clin Perinatol</i>. 2012;39(1):239-254.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/22341549 /pubmed\" target=\"_blank\" id=\"22341549 \">22341549 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hatab SZ, Singh A, Felner EI, Kamat P. Transient central diabetes insipidus induced by ketamine infusion. <i>Ann Pharmacother</i>. 2014;48(12):1642-1645.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/25225198 /pubmed\" target=\"_blank\" id=\"25225198 \">25225198 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/18245435 /pubmed\" target=\"_blank\" id=\"18245435 \">18245435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinrich M, Wetzstein V, Muensterer OJ, Till H. Conscious sedation: Off-label use of rectal S(+)-ketamine and midazolam for wound dressing changes in paediatric heat injuries. <i>Eur J Pediatr Surg</i>. 2004;14(4):235-239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15343462 /pubmed\" target=\"_blank\" id=\"15343462 \">15343462 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jobeir A, Galal MO, Bulbul ZR, et al, &quot;Use of Low-Dose Ketamine and/or Midazolam for Pediatric Cardiac Catheterization,&quot; <i>Pediatr Cardiol</i>, 2003, 24(3):236-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/12545318/pubmed\" target=\"_blank\" id=\"12545318\">12545318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koruk S, Mizrak A, Gul R, Kilic E, Yendi F, Oner U. Dexmedetomidine-ketamine and midazolam-ketamine combinations for sedation in pediatric patients undergoing extracorporeal shock wave lithotripsy: a randomized prospective study. <i>J Anesth</i>. 2010;24(6):858-863.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/20924617/pubmed\" target=\"_blank\" id=\"20924617\">20924617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lago P, Garetti E, Merazzi D, et al. Guidelines for procedural pain in the newborn. <i>Acta Paediatr</i>. 2009;98(6):932-939.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/19484828 /pubmed\" target=\"_blank\" id=\"19484828 \">19484828 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lahti AC, Koffel B, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. <i>Neuropsychopharmacology</i>. 1995 Aug;13(1):9-19<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/8526975/pubmed\" target=\"_blank\" id=\"8526975\">8526975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin C, Durieux ME. Ketamine and kids: an update. <i>Paediatr Anaesth</i>. 2005;15(2):91-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15675923 /pubmed\" target=\"_blank\" id=\"15675923 \">15675923 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin SM, Liu K, Tsai SK, Lee TY. Rectal ketamine versus intranasal ketamine as premedicant in children. <i>Ma Zui Xue Za Zhi</i>. 1990;28(2):177-183.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/2215104 /pubmed\" target=\"_blank\" id=\"2215104 \">2215104 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Little B, Chang T, Chucot L, et al, &quot;Study of Ketamine as an Obstetric Anesthetic Agent,&quot; <i>Am J Obstet Gynecol </i>, 1972, 15:113(2):247-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/4554554/pubmed\" target=\"_blank\" id=\"4554554\">4554554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louon A, Reddy VG. Nasal midazolam and ketamine for paediatric sedation during computerised tomography. <i>Acta Anaesthesiol Scand</i>. 1994;38(3):259-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/8023666/pubmed\" target=\"_blank\" id=\"8023666\">8023666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyon F, Dabbs T, and O'Meara M, &quot;Ketamine Sedation During the Treatment of Retinopathy of Prematurity,&quot; <i>Eye (Lond)</i>, 2008, 22(5):684-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. <i>Neuropsychopharmacology</i>. 1997 Sep;17(3):141-150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/9272481/pubmed\" target=\"_blank\" id=\"9272481\">9272481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. <i>Br J Anaesth</i>. 1996;77(2):203-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/8881626 /pubmed\" target=\"_blank\" id=\"8881626 \">8881626 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGlone RG, Howes MC, Joshi M. The Lancaster experience of 2.0 to 2.5 mg/kg intramuscular ketamine for paediatric sedation: 501 cases and analysis.<i> Emerg Med J</i>. 2004;21(3):290-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15107365 /pubmed\" target=\"_blank\" id=\"15107365 \">15107365 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mercier FJ, Benhamou D. Promising non-narcotic analgesic techniques for labour. <i>Baillieres Clin Obstet Gynaecol</i>. 1998;12(3):397-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/10023428/pubmed\" target=\"_blank\" id=\"10023428\">10023428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagdeve NG, Yaddanapudi S, Pandav SS. The effect of different doses of ketamine on intraocular pressure in anesthetized children. <i>J Pediatr Ophthalmol Strabismus</i>. 2006 Jul-Aug;43(4):219-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/16915900/pubmed\" target=\"_blank\" id=\"16915900\">16915900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nielsen BN, Friis SM, R&oslash;msing J, et al. Intranasal sufentanil/ketamine analgesia in children. <i>Paediatr Anaesth</i>. 2014;24(2):170-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/24118506 /pubmed\" target=\"_blank\" id=\"24118506 \">24118506 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norambuena C, Ya&ntilde;ez J, Flores V, Puentes P, Carrasco P, Villena R. Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study. <i>J Pediatr Surg</i>. 2013;48(3):629-634.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/23480923 /pubmed\" target=\"_blank\" id=\"23480923 \">23480923 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozdemir D, Kayserili E, Arslanoglu S, Gulez P, Vergin C. Ketamine and midazolam for invasive procedures in children with malignancy: a comparison of routes of intravenous, oral, and rectal administration. <i>J Trop Pediatr</i>. 2004;50(4):224-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15357562 /pubmed\" target=\"_blank\" id=\"15357562 \">15357562 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel P and Sun L, &quot;Update on Neonatal Anesthetic Neurotoxicity: Insight Into Molecular Mechanisms and Relevance to Humans,&quot; <i>Anesthesiology</i>, 2009, 110(4):703-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/19276968/pubmed\" target=\"_blank\" id=\"19276968\">19276968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pees C, Haas NA, Ewert P, et al, &quot;Comparison of Analgesic/Sedative Effect of Racemic Ketamine and S(+)-Ketamine During Cardiac Catheterization in Newborns and Children,&quot; <i>Pediatr Cardiol</i>, 2003, 24(5):424-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/14627307/pubmed\" target=\"_blank\" id=\"14627307\">14627307</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rock MJ, Reyes de la Rocha S, L'Hommedieu CS, Truemper E. Use of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapy. <i>Crit Care Med</i>. 1986;14(5):514-516.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/3698618 /pubmed\" target=\"_blank\" id=\"3698618 \">3698618 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roelofse JA, Shipton EA, de la Harpe CJ, Blignaut RJ. Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison. <i>Anesth Prog</i>. 2004;51(4):114-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15675259 /pubmed\" target=\"_blank\" id=\"15675259 \">15675259 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M, Rieder M. A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children. <i>Ann Emerg Med</i>. 2011;57(5):425-433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/20947210 /pubmed\" target=\"_blank\" id=\"20947210 \">20947210 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soto E, Stewart DR, Mannes AJ, et al. Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome. <i>Am J Hosp Palliat Care</i>. 2012; 29(4): 308&ndash;317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/21803784/pubmed\" target=\"_blank\" id=\"21803784\">21803784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sungur Ulke Z, Kartal U, Orhan Sungur M, Camci E, Tugrul M. Comparison of sevoflurane and ketamine for anesthetic induction in children with congenital heart disease. <i>Paediatr Anaesth</i>. 2008 Aug;18(8):715-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/18544145 /pubmed\" target=\"_blank\" id=\"18544145 \">18544145 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surendar MN, Pandey RK, Saksena AK, Kumar R, Chandra G. A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. <i>J Clin Pediatr Dent</i>. 2014;38(3):255-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/25095322 /pubmed\" target=\"_blank\" id=\"25095322 \">25095322 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaka M, Sato M, Saito A, Nishikawa T. Reevaluation of rectal ketamine premedication in children: comparison with rectal midazolam. <i>Anesthesiology</i>. 2000;93(5):1217-1224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/11046209 /pubmed\" target=\"_blank\" id=\"11046209 \">11046209 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, Martin LD, Wetzel RC. Ketamine by continuous infusion for sedation in the pediatric intensive care unit. <i>Crit Care Med</i>. 1990;18(8):819-821.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/2379394 /pubmed\" target=\"_blank\" id=\"2379394 \">2379394 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, Phipps S, Smith B, et al, &ldquo;Oral Ketamine Premedication to Alleviate the Distress of Invasive Procedures in Pediatric Oncology Patients,&rdquo; <i>Pediatrics</i>, 1992, 90(4):537-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/1408506/pubmed\" target=\"_blank\" id=\"1408506\">1408506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, Rasmussen GE. Pain management and sedation in the pediatric intensive care unit. <i>Pediatr Clin North Am</i>. 1994;41(6):1269-1292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/7984386/pubmed\" target=\"_blank\" id=\"7984386\">7984386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomatir E, Atalay H, Gurses E, et al, &quot;Effects of Low Dose Ketamine Before Induction on Propofol Anesthesia for Pediatric Magnetic Resonance Imaging,&quot; <i>Paediatr Anaesth</i>, 2004, 14(10):845-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/15385013/pubmed\" target=\"_blank\" id=\"15385013\">15385013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turhano&#287;lu S, Kararmaz A, Ozyilmaz MA, Kaya S, Tok D. Effects of different doses of oral ketamine for premedication of children. <i>Eur J Anaesthesiol</i>. 2003;20(1):56-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/12553389/pubmed\" target=\"_blank\" id=\"12553389\">12553389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Bijl P, Roelofse JA, Stander IA. Rectal ketamine and midazolam for premedication in pediatric dentistry. <i>J Oral Maxillofac Surg</i>. 1991;49(10):1050-1054.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/1890517 /pubmed\" target=\"_blank\" id=\"1890517 \">1890517 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner BK, O'Hara DA. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. <i>Clin Pharmacokinet</i>. 1997;33(6):426-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/9435992 /pubmed\" target=\"_blank\" id=\"9435992 \">9435992 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Zhou ZJ, Zhang XF, Zheng S. A comparison of two different doses of rectal ketamine added to 0.5 mg x kg(-1) midazolam and 0.02 mg x kg(-1) atropine in infants and young children. <i>Anaesth Intensive Care</i>. 2010;38(5):900-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/20865876 /pubmed\" target=\"_blank\" id=\"20865876 \">20865876 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weksler N, Ovadia L, Muati G, Stav A. Nasal ketamine for paediatric premedication. <i>Can J Anaesth</i>. 1993;40(2):119-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/8443849 /pubmed\" target=\"_blank\" id=\"8443849 \">8443849 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White PF, Way WL, and Trevor AJ, &quot;Ketamine &minus; Its Pharmacology and Therapeutic Uses,&quot; <i>Anesthesiology</i>, 1982, 56(2):119-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/6892475/pubmed\" target=\"_blank\" id=\"6892475\">6892475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willman EV, Andolfatto G. A prospective evaluation of &quot;ketofol&quot; (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2007;49(1):23-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/17059854 /pubmed\" target=\"_blank\" id=\"17059854 \">17059854 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yan J, Li YR, Zhang Y, Lu Y, Jiang H. Repeated exposure to anesthetic ketamine can negatively impact neurodevelopment in infants: a prospective preliminary clinical study. <i>J Child Neurol</i>. 2014;29(10):1333-1338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/24659739/pubmed\" target=\"_blank\" id=\"24659739\">24659739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Youssef-Ahmed MZ, Silver P, Nimkoff L, Sagy M. Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm. <i>Intensive Care Med</i>. 1996;22(9):972-976.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/8905436 /pubmed\" target=\"_blank\" id=\"8905436 \">8905436 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zanette G, Micaglio M, Zanette L, Manani G, Facco E. Comparison between ketamine and fentanyl-droperidol for rectal premedication in children: a randomized placebo controlled trial. <i>J Anesth</i>. 2010;24(2):197-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-pediatric-drug-information/abstract-text/20157833 /pubmed\" target=\"_blank\" id=\"20157833 \">20157833 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13398 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45497290\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F185726\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053466\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675070\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053458\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F185708\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F185693\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F185765\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053471\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F185722\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053470\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F185772\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F185769\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F185713\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F185697\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26021157\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F185759\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F185702\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5994626\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053465\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F185696\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F185712\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422244\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F185716\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13398|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine: Drug information</a></li><li><a href=\"topic.htm?path=ketamine-patient-drug-information\" class=\"drug drug_patient\">Ketamine: Patient drug information</a></li></ul></div></div>","javascript":null}